Rani A. Habash advises clients on the antitrust aspects of mergers, acquisitions, and joint ventures. He has helped guide industry-leading companies to successful strategic transactions in the face of intense antitrust scrutiny by the U.S. Department of Justice, U.S. Federal Trade Commission, Senate and House Judiciary Committees, state attorneys general, and international competition authorities.
Using his expertise in economics and significant experience in dealing with antitrust agencies, Mr. Habash has helped clients secure regulatory clearance in numerous high-profile transactions, including deals between American Airlines/US Airways, Albertsons/Safeway, CVS Health/Aetna, CVS Health/Target Corporation, FMC Corporation/DowDuPont, Medco/Express Scripts, Monster.com/Yahoo! HotJobs, and OfficeMax/Office Depot, among others. In addition, Mr. Habash defends companies in government antitrust investigations and helps them further key corporate strategies by providing antitrust counseling on conduct, distribution, government affairs, and public relations issues.
Mr. Habash was recognized as a "Future Leader" by Who's Who Legal in its 2020, 2021, and 2022 Competition guide. The National Law Journal named Mr. Habash a “D.C. Rising Star” in 2019. This award recognized lawyers for the substantial legal influence they wield within their practice areas and as innovators with strong leadership qualities, superior legal expertise, and a commitment to pro bono, charitable, and professional volunteer work.
Mr. Habash has held leadership positions in the ABA’s Section of Antitrust Law on the Mergers & Acquisitions, Corporate Counseling, and Membership and Diversity Committees. He also served as the editor of The Antitrust Counselor, an ABA newsletter with practical antitrust guidance for in-house counsel.
Mr. Habash is a frequent author and speaker on cutting-edge antitrust issues. Notably, he has helped develop the Dechert Antitrust Merger Investigation Timing Tracker (DAMITT), which tracks and reports on U.S. antitrust merger investigation trends. Data from DAMITT has been cited by The Wall Street Journal, Fortune, Time, TheStreet, and many other leading publications.
*****
A person listed as a contributor has spoken or otherwise participated in Federalist Society events, publications, or multimedia presentations. A person's appearance on this list does not imply any other endorsement or relationship between the person and the Federalist Society. In most cases, the biographical information on a person's "contributor" page is provided directly by the person, and the Federalist Society does not edit or otherwise endorse that information. The Federalist Society takes no position on particular legal or public policy issues. All expressions of opinion by a contributor are those of the contributor.
FTC’s Interim Pharmacy Benefit Manager Report - Assessing Vigor
On July 9th, the Federal Trade Commission released a Staff Interim Report on the Pharmacy...
FTC’s Interim Pharmacy Benefit Manager Report - Assessing Vigor
On July 9th, the Federal Trade Commission released a Staff Interim Report on the Pharmacy...